2014 Investor Day Conference

53 %
47 %
Information about 2014 Investor Day Conference
Investor Relations

Published on March 11, 2014

Author: ir_stjude

Source: slideshare.net

St. Jude Medical 2014 Investor Conference February 7, 2014

22 Welcome and Opening Remarks Dan Starks, Chairman, President and CEO

33 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 29, 2012 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 28, 2013. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance. Forward-Looking Statements

44 Agenda 8:00 a.m. Overview of St. Jude Medical’s 2014 growth program.  Dan Starks, Chairman, President and Chief Executive Officer EPS leverage in 2014 and beyond.  Don Zurbay, Vice President, Finance and Chief Financial Officer Highlights of our CRM business.  Eric Fain, M.D., Group President The CardioMEMS™ HF System can become a significant new growth driver.  Lisa Andrade, Vice President and Chief Marketing Officer Panel for Q&A 10:00 a.m. Break Power of the EP portfolio. Eric Fain, M.D., Group President A special focus on Endosense.  Srijoy Mahapatra, M.D., FHRS, Vice President, Clinical, Medical and Scientific Affairs Executing on a robust CV portfolio.  Eric Fain, M.D., Group President A deeper dive into Portico™ transcatheter aortic valve. Phil Ebeling, Senior Vice President, Research and Development Growth through innovation in neuromodulation.  Eric Fain, M.D., Group President Panel for Q&A Lunch Buffet 12:30 p.m. Meeting Ends

55 Overview of St. Jude Medical’s 2014 Growth Program

66 We accomplished our major growth goals in 2013.  On a constant currency basis, we delivered adjusted EPS growth of 12% on 2% growth in revenue.*  We accelerated our sales growth rate each quarter starting the year with a 3% decline in Q-1 and ending the year with a 6% increase in Q-4. * All sales growth values in this presentation are expressed on a constant currency, year-over-year basis.

77 Sales growth improvement was broad based due to encouraging market dynamics and new products launched in every business. 1H 2013 2H 2013 High voltage (2%) 4% Low voltage (8%) 1% Vascular 1% 3% Structural Heart 2% 8% Neuro (1%) 2% AF 10% 9% Total (1%) 4%

88 We view ourselves as a company that entered 2014 with sales growing at an annual rate of approximately 4%.  This is consistent with the guidance we gave on our Q-4 earnings call that sales would increase approximately 3- 5% in 2014.  It usually is more meaningful to consider sales rates based on at least two quarter’s results (4% increase 2H 2013) instead of on a single quarter’s results (6% increase Q-4 2013).

99 Looking forward to our sales growth in 2014

1010 St. Jude Medical’s growth program is based on innovation. We provide innovative medical devices that help reduce the cost of health care and improve patient outcomes for some of our most expensive, epidemic diseases.  Heart rhythm disorders  Atrial fibrillation  Heart failure  Hypertension  Chronic pain  Stroke  Coronary artery disease  Structural heart defects

1111 We estimate that the markets we participate in exceed $20 billion in size and are growing at an average rate of approximately 4%. Potential markets (CardioMEMS™ HF System, renal denervation) provide upside. Size Market $ billions Growth % CRM 10.8 - 0 - Structural Heart 3.1 9% AF 2.9 9% Vascular 1.8 6% Neuro 2.0 5% 20.6

1212 We expect our growth rate to benefit from a tailwind as our sales mix shifts to products in faster growing markets. Legacy markets Growth driver markets CRM* AF Mechanical heart valves Tissue and TAVR heart valves Vascular closure Fractional flow reserve (FFR) Third party Japan Optical coherence tomography (OCT) Chronic Pain CardioMEMS™ HF System Left atrial appendage closure (LAA) Deep brain stimulation Renal denervation * Revenue from CRM products was 59% of our sales mix in 2010 compared with 51% in 2013.

1313 We have the right products in the right markets to accelerate our sales growth over time.  We have plenty of opportunity.  Our primary focus therefore is execution.

1414 The organizational and leadership changes we have made since Q-4 2012 are helping us improve our execution.  Our customers are changing. We are changing with them.  It no longer makes sense to organize by physician specialty in a decentralized structure.  Our transition to a centralized structure helps us leverage our scale, align our priorities, capture technology synergies, improve our quality, and strengthen our focus on the new customer profile that is emerging as a result of health care reform and structural changes to the health care market.

1515 Our execution is focused on accomplishing all of the following goals in 2014.  Meet or exceed the guidance we gave on our Q-4 earnings call.  Accelerate our sales growth rate during the year.  Exit 2014 capable of delivering both EPS leverage and mid to high single digit sales growth in 2015.* * We are not yet issuing guidance for 2015.

1616 Key execution milestones for 2014

1717 We expect to resolve our Sylmar FDA warning letter and improve our flow of new product launches in the U.S. for our CRM business.  Allure Quadra™ CRT-P and our next generation low voltage platform of devices (Endurity™ and Assurity™ pacemakers) have been launched in Europe in 2013 and are approvable in the U.S. pending resolution of the warning letter.

1818 We expect to resolve our Plano FDA warning letter and accelerate neuromodulation sales growth with new products.  Prodigy™ spinal cord stimulation (SCS) with SJM Burst technology in Europe.  Protégé™ spinal cord stimulation (SCS) platform in the U.S.  Submit our PMA for deep brain stimulation (DBS) for Parkinson’s disease and Essential Tremor indications in the U.S.

1919 We expect to accelerate sales growth in our AF franchise.  The primary catalyst will be a successful ramp-up and launch of our TactiCath™ line of contact force sensing ablation catheters (our Endosense acquisition). Impact should be visible 2H 2014 as manufacturing ramp-up is completed.  A secondary catalyst will be the expanded roll out of our MediGuide™ technology together with the effect this has on adoption of our complete AF and CRM bundles.

2020 We expect our Nanostim™ retrievable leadless pacemaker product line launch to begin impacting sales growth 2H 2014.  Manufacturing ramp-up is underway and should be completed by mid 2014.  Early KOL feedback encourages us that the Nanostim™ leadless pacemaker platform can evolve into a significant new growth driver.  This is a disruptive technology.

2121 Our Portico TAVR program is expected to contribute higher sales each quarter of 2014.  Our 23mm Portico™ heart valve with a transfemoral (TF) delivery system was on the market in Europe in 2013 but addressed less than 10% of the market.  We received CE mark for our 25mm Portico™ heart valve with a TF delivery system in December 2013. Launch in Europe already is underway.  We expect to launch our 27mm and 29mm Portico™ heart valve products with TF delivery systems in Europe during 2H 2014.

2222 We are enthusiastic about the significant impact the CardioMEMS™ wireless heart failure (HF) sensor can provide to Class III HF patients.  CHAMPION trial 1. 28% reduction in hospital readmissions at 6 months. 2. 37% reduction in heart failure hospital readmissions at 17 months.  This technology has the potential to provide significant clinical and economic benefits for patients who suffer from Class III heart failure and become a major new growth driver. * CardioMEMS is an independent, privately held company in which STJ holds an equity interest and an exclusive option to acquire the company.

2323 We expect new products and expanded programs throughout our business to help maintain or improve our sales growth rate in 2014.  Continued role out of the dorsal root ganglion stimulation (DRG) technology for chronic pain.  Expansion of our FFR, OCT, and LAA closure programs.  We remain optimistic about renal denervation as a potential new growth driver. We look forward to reviewing the SYMPLICITY HTN-3 clinical trial results and incorporating lessons learned into our renal denervation program.

24 Summary of our sales growth expectations.  We entered 2014 with sales growing at an annual rate of approximately 4%.  Our sales growth rate should improve as our product mix continues to shift to faster growing markets.  We expect to launch multiple new growth drivers in 2014, including CRM products in the U.S., Nanostim™ leadless pacemaker, TactiCath™ ablation catheter, CardioMEMS™ HF system, 25mm-29mm sizes of Portico™ heart valve, Prodigy™ SCS with Burst, Protégé™ SCS with upgradeability, and more.  Our goal is to accelerate our sales growth rate during the year and exit 2014 capable of delivering mid to high single digit sales growth in 2015.

EPS leverage in 2014 and beyond Don Zurbay, Vice President and Chief Financial Officer

2727 We are well positioned to continue delivering EPS leverage in 2014 and beyond.  Our 2014 guidance calls for sales growth of 3 – 5% and EPS growth of 6 – 8%.  We are continuing to expand manufacturing in cost advantaged locations.  We see significant opportunity to continue taking costs out of our business with our on-going restructuring programs.  We expect economies of scale to evolve for each of our new growth drivers.

28 We are well positioned to maintain or improve our gross margin beyond 2014.  Our gross margin is impacted by both positive and negative factors.  Excise taxes provide a 50 basis point headwind to our gross profit margin in 2014.  Additionally, we are negatively impacted by geographic and product mix shifts and lower average selling prices.  We expect to offset the negative factors through continued expansion of our manufacturing in cost advantaged locations and other continuous improvement initiatives.  The negative gross margin impact of our growth drivers will improve as volumes increase and manufacturing improvements are realized.

2929 Opportunities to leverage our global operations and supply chain  Centralization of our world-wide manufacturing organization will further enable us to optimize our $1.6 billion in global operations spending.  We are currently manufacturing approximately 60% of our worldwide volume in cost advantaged locations with an internal goal of reaching 80%.  Our cost advantaged facilities are at varying stages of utilization and we have ample capacity to support our revenue growth over the next five years.

3030 Optimization of our cost structure  From 2011 to 2013, S,G&A expenses have been reduced by approximately 170 basis points as a percentage of sales in a low sales growth environment.  Acceleration of sales growth provides a natural leverage point to the fixed component of our cost structure  Our current organization has ample capacity to support our increased sales.  Growth drivers require investment similar to a start up company and our ratios will improve as we start to generate meaningful sales.  Moving forward the negative impact of variable interest entity accounting will ease.

3131 Optimization of our cost structure  We estimate that we have already generated over $100 million in incremental cost savings as a result of the restructuring actions announced in 2012 .  We expect additional leverage and productivity improvements in 2014 and beyond as a result of these actions as well as the changes announced last week.  The optimization of our cost structure allows us to remain committed to our innovation-based growth strategy with our investment in R&D consistently being greater than 12% of sales.

32 OUS Manufacturing's effect on the Tax Rate  The largest driver of our tax rate improvement is expansion of manufacturing in cost advantaged locations. 24.5% 22.0% 21.6% 20.9% 18.5% 16.0% 18.0% 20.0% 22.0% 24.0% 26.0% 2010 2011 2012 2013 2014 2010 2011 2012 2013 2014 24.5% 22.0% 21.6% 20.9% 18.5%

3333 We maintain a conservative balance sheet which continues to benefit from strong and consistent cash flow.  Balances as of December 31, 2013:  Cash on hand $1.4 billion  Debt outstanding $3.6 billion Current credit ratings: Moody’s – Baa1, S&P – A, Fitch – A  For the three years ended 2013, we have generated cash flow from operations of approximately $3.6 billion, 22% of net sales.  We have ample capacity to continue returning capital to shareholders while maintaining the capacity to augment our growth strategy with disciplined acquisitions.

3434 Dividends and Share Repurchases  Since 2011, the Company has completed $2.8 billion of share repurchases with an average purchase price of $43.47 per share.  Share repurchases will manage the dilutive impact of our stock based compensation.  In February of 2011, the Company initiated a dividend and we have increased our dividend an average of 9% annually.  The share repurchases and growth in dividend reflects the strong confidence our management team and our board of directors have in our long-term growth and success.

3535 Summary  Our goal is to continue growing sales at a 3% to 5% rate for full year 2014 and create the conditions to support faster sales growth in 2015.  We expect to continue delivering EPS leverage in 2014 and beyond.  We have a conservative balance sheet and strong cash flow to continue to repurchase stock, increase our dividend, and fund disciplined acquisitions as appropriate.

Highlights of our CRM business Eric S. Fain, M.D. – Group President

38 2013 CRM Highlights  Core CRM markets stabilizing and showing signs of growth  Acceleration of implant growth rates WW throughout the year  Stabilizing ASP trends  Accelerated our sales growth each quarter:  Exited year with share capture in both LV and HV  Market Share leader in U.S. De Novo CRT-D  Third party analysis of STJ data as well as independent large hospital system experience confirmed the strong performance of Durata™ lead  Over 425,000 leads implanted WW and >6 years of follow-up  De Novo lead-to-port ratio returned to parity with device sales  Expanded our Industry leading product portfolio  Launched new ICD (WW) and pacemaker (Int’l) platforms  Extended our quadripolar leadership with MPP and CRT-P (Int’l)  Significant progress in remediation of Sylmar warning letter  We anticipate FDA re-inspection by the end of 1H 2014

39 Implantable Electronic Systems: Leveraging Operational Synergies in 2013  Capitalized on the combined strength of our organization and rapidly achieved functional integration:  Reduced costs and improved effectiveness by leveraging a single integrated R&D organization and associated core competencies  Began implementing operational synergies that enhance quality and improve cost structure while also leveraging our existing cost advantaged manufacturing locations  Leveraged integrated clinical study and field clinical engineering organizations to improve execution and timelines  Additional opportunities in the future as we move to common electronics and externals platforms

40 2014 WW CRM Market Dynamics  Expect the 2013 global CRM market to be flat versus 2012 on a CC basis  Renewed unit growth but continued ASP pressure  2H 2013 likely up about 2% vs. 2H 2012 on a CC basis  The mid-point of our guidance range assumes the CRM market is flat in 2014 vs. 2013 (on an “as reported” basis)  Our model assumes a CRM market of $10.8 billion in 2014  We expect to gain 50 bps of CRM share in 2014:  Differentiated product portfolio  HV replacement tailwind

41 17% 19% 21% 23% 25% 27% 29% 31% 33% 2010 2011 2012 2013 2014 2015 2016 2017 2018 EstimatedMarketShare 2013 Year End De Novo Share (Est.) Year End Replacement Share (Est.) Linear Trend to Current De Novo Share 2012 Year End De Novo Share (Est.) Replacement Share Share Delta of ~6.5% Est. +2.0% in 2013 2012 De Novo Share 2013 De Novo Share U.S. HV Replacement Market Dynamics Our replacements tailwind will continue to support market share capture

CRM Portfolio Highlights

4343 Continued Innovation across Product Portfolios Right Products at the Right Time SJM Quadra family of devices with MultiPoint™ Pacing Nanostim™ Leadless Pacemaker CardioMEMS™ HF System Allure Quadra™ CRT-P

4444 Quadripolar Pacing – Standard of Care in CRT Strong clinical evidence driving continued CRT-D share gains  U.S. De Novo market share leader in CRT-D  Will remain the only quadripolar system available in U.S. in 2014  Only next generation MPP system in International markets  Over 100 publications provide broad clinical evidence supporting the benefits of the quadripolar system at implant and follow-up  Clinical benefits also translate into healthcare economic benefits Estimated U.S. CRT-D De Novo Market Share 27% 29% 31% 33% 35% 37% 39% 41% 2011 2012 2013

45 Distal 1 Mid 3 Proximal 4 Mid 2 Common Pacing Complications with Bipolar CRT Addressed with Quadripolar System Four electrodes and 10 pacing vectors Allows implant without trading off stability for electrical performance

46 Quadripolar benefits can lower both the near-term and long-term overall cost of care Positive impact to hospitals, ACOs, bundled payment sites and payers More pacing options to manage implant complications 100% Resolution of Phrenic Nerve Stimulation without surgical lead revision (SLR)1 Significant reduction in surgical lead revisions when compared to bipolar leads2 Better device longevity3 Patients with high LV thresholds could see significant longevity improvement of up to 17 months using unique quadripolar vectors Proven efficacy on both objective and subjective measures of HF improvement4 LV volumes, EF and 6-minute walking distance / MN Quality of Life score4 Overall, 66% of patients improved at least 1 class on NYHA scale Lowered rate of LV lead deactivation/ replacement5 53% of patients programmed to a unique quadripolar vector to avoid pacing complication and possible surgical lead replacement pic 1. Zanon et al. Heart Rhythm, Vol. 10, No 5, May 2013. New Onset of Phrenic Nerve Stimulation During Left Ventricular Pacing at Mid-Term Follow Up: A Multicenter Clinical Experience. 2. Viani SM, et al. A new quadripolar lead for left ventricular pacing: short term reliability and future opportunities. Europace. 2011; 13(3), Abstract P408 3. Manyam et al. Heart Rhythm, Vol. 10, No 5, May 2013. Quadripolar Left Ventricular Leads Yield Lower Capture Thresholds With Expected Increase In Battery Longevity. 4. Forleo GB, et al. Heart Rhythm 2012; 9 (11), 1822-1828.e3 5. Turakhia et al. Heart Rhythm, Vol.10, No 5, May 2013. Decreased Risk of Left Ventricular Lead Deactivation and Replacement Associated With Quadripolar LV Leads.

47 1. Tomassoni, G. et al. Post operative performance of a novel left ventricular quadripolar electrode lead. Heart Rhythm. 2011;8(5):S119 (Abs. PO1-43). 2. Thibault B, et al. Electrode Selection to Avoid Phrenic Stimulation with a Quadripolar Left Heart Lead. Heart Rhythm. 2011;8(5):S68 (Abs. AB30-3). 3. Dänschel W, et al. Initial Clinical Experience with a Novel Left Ventricular Quadripolar Lead. Oral Session 183/5. Europace, 2010; 12 (suppl 1): i127. 4. Osca J, et al. Initial Experience with a New Quadripolar Cable for Left Ventricular Stimulation. Impact Over Phrenic Nerve Stimulation and Pacing Thresholds. Heart Rhythm. 2011;8(5):S359 (Abs. Po5-14). 5. Mehta PA, Shetty AK, Squirrel M, et al. Elimination of phrenic nerve stimulation occurring during CRT : Follow-up in patients implanted with a novel quadripolar pacing lead. J Interv Card Electrophysiol 2011 Jul 21. 6. Viani SM, et al. A New Quadripolar Lead For Left Ventricular Pacing: Short Term Reliability and Future Opportunities. Europace 2011 (Abstract). Clinical results show consistently strong performance Reduction in RevisionsPNS Resolution Tomassoni1 Thibault2 Danschel3 Osca4 Mehta5 6

48 Clinical Superiority of Quadripolar Technology  NCDR ICD Registry is a national, prospective database managed by the ACC in collaboration with HRS  Updated analysis used NCDR ICD Registry data for implants performed from January 1, 2012 through June 30, 2013  STJ quadripolar CRT Technology demonstrated an 89% reduction of failed implants over non-quadripolar LV leads from all manufacturers  Additional publications expected in 2015 highlighting improved outcomes and mortality Non-Quad STJ Quadra P-value 1H 2012 4.20% 0. 51% <0.0001 2H 2012 4.53% 0.49% < 0.0001 1H 2013 4.20% 0.49% < 0.0001 Total (N=56,656) 4.30% 0.49% < 0.0001 NCDR ICD Registry Failed LV Lead Implants* * Reasons LV leads were not implanted include diaphragmatic stimulation, unacceptable thresholds, and target vein/coronary sinus access

49 Quadra Assura™ CRT-D MultiPoint™ Pacing (MPP): Building clinical evidence with 2nd generation technology  Two-site LV stimulation extends the capabilities of Quadripolar technology platform with a focus on further improved patient outcomes  Studies demonstrate significant improvement compared to conventional biventricular pacing  Improved acute hemodynamics with an MPP configuration in large majority of patients1-4  Equivalent improvement seen in both ischemic and non-ischemic patients3,4  No difference between quadripolar lead and multi-branch (2 leads)5  Reduced rate of CRT non-responders  26% more CRT responders (ESV >15% reduction) after 3-month of MPP6  IDE enrollments expected to complete in 2014 1. Rinaldi et al. Acute hemodynamic benefits of multisite LV pacing in CRT recipients. Abstract ACC 2012 2. Thibault et al. Acute hemodynamic comparison of multisite and biventricular pacing with a quadripolar LV lead. Europace 2013 ;15:984-991 3. Pappone et al. Multipoint LV pacing improves acute hemodynamic response assessed with pressure-volume loops in CRT patients. Heart Rhythm 2014 (in press) 4. Rinaldi et al. Acute effects of multisite LV pacing on mechanical dyssynchrony in patients receiving CRT. J Cardiac Failure 2013;19:731-738 5. Shetty et al. A comparison of LV endocardial, multisite and multipolar epicardial cardiac resynchronization: An acute hemodynamic and electro-anatomical study. Europace 2014 (in press) 6. Pappone et al. Multipoint LV pacing in a single coronary sinus branch Improves 3-month echocardiographic and clinical response to CRT. Abstract HFSA 2013

5050 Allure Quadra™ CRT-P  Strong demand and driving share capture in Int’l markets  Significant competitive advantage in an estimated $420M WW CRT-P market  Expands quadripolar portfolio to fastest growing CRM segment  Market size expected to double in the next 5 years with new indications  No known competitive quadripolar pacemakers in pipeline  Capitalize on rapid growth in the CRT-P segment driven by BLOCK HF results (AHA 2012) and BIOPACE (2H 2014)  Significant appeal to pacer implanters who begin implanting CRT-P  Leverages new LV platform for improved cost structure $200 $250 $300 $350 $400 $450 2011 2012 2013 2014 $MM Estimated CRT-P Market Revenue WW Market Size 11% CAGR

51  Expanding portfolio of quadripolar lead options  3 lead shape options  2 electrode spacing options to facilitate basal pacing  All spacing options maintain 4 discrete electrode locations for pacing vector selection  Smaller diameter for easier access to tortuous anatomy  Designed for MRI compatibility Quartet™ NXT LV Leads Extending Quadripolar Leadership with 2nd generation technology

52 Leadership in Low Voltage Platform in 2014 Assurity™ and Endurity™ Allure Quadra™ Accent MRI™ Nanostim™ Significant technology advantages to drive share gains in ~$4B low voltage market

5353 Brady MRI Compatibility  Industry best lead handling  No scan zone/power restrictions  Efficient workflow using the STJ MRI activator  Continued success in Int’l markets  Strong adoption following launch in Japan  Accent MRI IDE Study: Expect to complete MRI scans and follow-up in 2H 2014  Will continue to expand product portfolio of MRI compatible devices  Expect to launch restricted MRI models in Int’l markets in 2014 for tiering

5454 Nanostim™ Leadless Pacemaker  Specifically designed for repositioning and chronic retrievability (catheter-based)  Energy efficient design  High-capacity battery  No losses due to lead conductor resistance  Proprietary low-power “conducted communication”  Designed to prevent dislodgement  Double fixation: single turn helix (x 2 pull-strength) plus angled nylon sutures  Radiographic indicator to ensure proper number of turns  Tethered test mode for intraoperative evaluation  Delivered via 18F introducer  Supported by Merlin™ Patient Care System First and only commercially available leadless pacing system

5555 Standard Pacemaker Leadless Pacemaker Implant procedure Surgical pocket + lead Percutaneous femoral based Implant time 30 – 45 minutes 15-20 minutes Cosmetics Scar, Visible Device No Scar, No Visible Device Post-Implant Restrictions Limited arm movements Wound care/ sutures No heavy lifting Minimal (faster patient recovery) Connections Lead-can connectors None Chronic tricuspid valve interference Yes (lead) No (leadless) Longevity 9-13 years 9-19 years Battery Replacement Pocket access Femoral access MRI compatibility Conditional – image impact Inherently MRI compatible Comparison with Conventional Lead-Based System

5656 Complication Occurrence Leadless Advantage Lead dislodgement 2.2% to 3.7% Not applicable/ No lead Low risk of device dislodgement Pneumothorax 1.6% to 2.6% No Risk - Not applicable Lead perforation 0.5%-1% Not applicable – No Lead Low risk of device perforation Venous thrombosis 1%-3% No Risk – Not applicable Chronic Lead failure 2%-4% of pts at 5 years Not applicable – No Lead Hematoma requiring surgical evacuation <0.5% Reduced Risk Skin erosion (generator change) 0.8-0.9% No Risk – No Pocket Pocket Infection • < 1% for single- chamber • 3-5% for generator change No Risk – No Pocket Complications Associated with Pacemakers

57 Launch Summary  Initial launch feedback and enthusiasm in EU has been even greater than anticipated  Strong success with initial implants driving continued demand  Strong interest from historically non-STJ customers  Unprecedented interest in U.S. IDE study  Strong interest in Japan/Asia due to lack of scar/visible device  Significant media attention and coverage driving patient awareness  Significant market opportunity in ~$700M single-chamber pacemaker segment

58 Clinical Summary LEADLESS Study: First in Man  Successful delivery in 32/33 patients (97%)  Short Procedure Times  Introducer in/out: 28 minutes  Catheter in/out: 16 minutes  Excellent pacing and sensing performance LEADLESS II IDE Study  PMA Submission requirement: 300 patients followed for 6 months  First implants Feb 2014 Leadless Pacemaker Observational Study (International)  1000 patients at ~100 sites followed for 5 years  Enrollment underway

5959 Nanostim™ Dual Chamber Leadless Pacemaker  Dual chamber pacemakers represent >70% of worldwide pacing market  Approximately $3B market in 2014  Development work underway to expand Nanostim technology  Single chamber development helps validate delivery and dual chamber feasibility  Low power conducted telemetry scheme can be leveraged for device-to-device communication resulting in low impact to device longevity  Communication between devices demonstrated in animal studies

60 Summary of CRM Highlights for 2014  The global CRM market has stabilized  We expect to gain share in the high voltage segment due to replacement market dynamics and leadership in quadripolar CRT-D  The Nanostim™ leadless pacemaker and our Allure Quadra™ CRT-P product lines give us clear leadership in a $1 billion component of the low voltage segment  The midpoint of guidance that assumes we will gain approximately 50 basis points of share in a stable market is well supported and may be conservative  We have completed all remediation activities associated with the Sylmar site Form 483 and warning letter and we anticipate FDA re-inspection by the end of 1H 2014

The CardioMEMS™ HF System can become a significant new growth driver Lisa Andrade – Vice President and Chief Marketing Officer * CardioMEMS is an independent, privately held company in which STJ holds an equity interest and an exclusive option to acquire the company.

63 CardioMEMS™ HF System  Sensor with Delivery Catheter System  Permanent implant  No batteries or components that require replacement  Implanted into pulmonary artery  Uses a safe, well-understood right heart catheterization procedure  Electronics  Patient configuration  Hospital/clinic version  Website  PA pressure readings and trends  Systolic, Diastolic and Mean  PA pressure waveforms  Heart rate At-home In-hospital

64 Heart Failure Burden in the United States1,2  5.1M Americans suffer from HF  >650,000 new HF diagnoses each year  1 in 2 HF patients die in 5 years  Burden on healthcare system is high  2.8M office and ED visits each year  1.0M HF hospitalizations each year  Leading cause of hospitalizations among >65 years old patients  Every 30 seconds, someone is hospitalized for HF 1 Go A, et al. Heart Disease and Stroke Statistics 2013 Update: A Report from the American Heart Association. Circulation. Published online December 12, 2012. 2 Blecker, S, Paul, M et al. Heart failure-associated hospitalizations in the United States. JACC 2013 61:12 (1259-1267) Heart Failure is a growing and expensive public health issue of HF patients die in 5 years1 50% 5.1M

65 Economic Burden of HF Admissions in the US  Total cost of HF in the US expected to double by 20301  $31B/year in 2013, $70B/year in 2030  >1/2 of costs spent on hospitalizations2  5.1 day average hospital length of stay4  High readmission rates  25% readmission within 30 days2  50% readmission within 6 months3  1/5th of all Medicare admissions in the US have a diagnosis of heart failure5  Most HF patients suffer re-congestion within 60 days  Even at the best hospitals6 1 Go A, et al. Heart Disease and Stroke Statistics 2013 Update: A Report from the American Heart Association. Circulation. Published online December 12, 2012. 2 2013 ACCF/AHA Guideline for the Management of Heart Failure: A report of the ACC/AHA Task Force on Practice Guidelines. Circulation. Published online June 5, 2013. 3 Focus Update Incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: Circulation 2009;119; e391-e479(e437) 4 National Health Statistics, National Hospital Discharge Survey: 2007 Summary October 26,2010 5 Emory Healthcare. Heart Failure Statistics. Emory Healthcare [serial online]. Published 2013. Accessed April 2, 2013. 6 Lala, et al. for H-FAN. HFSA 2013 7 MEDPAC, Report to Congress: Promoting Greater Efficiency in Medicare, June 2007. Advisory Board Cardiovascular Roundtable Research & Analysis as reported in Publication 20286C entitled “Transformative Care Delivery, Part II: Reducing Preventable Readmissions.” $31 Billon annual Cost of HF in US1 5.1 days average hospital length of stay4 $600M spent annually on preventable Medicare HF patient readmissions7

66 New York Heart Association (NYHA) Class III Leads HF Admissions NYHA Class III patients have marked limitation in activity even during minimal activity. They are comfortable only at rest. 1 CVRG, 2007; McCullough, 2002; McAllister, 1999 [41-43} 2 Fonarow G, et al. Overview of Acutely Decompensated Congestive Heart Failure (ADHF): A Report from the ADHERE Registry. Heart Failure Reviews 9, 179-185, 2004 Approximately 1 in 3 HF Patients are NHYA Class III. These patients comprise almost half of the HF admissions. 29% 44% 0% 20% 40% 60% 80% 100% % of HF patients % of HF admissions NYHA I NYHA II NYHA III NYHA IV 1 2

67 Economic Risks of HF Readmissions in the US Medicare’s Hospital Readmissions Reduction (HRR) Program  Program penalizes hospitals who have above average risk adjusted all-cause readmissions within 30 days following HF, Acute MI, Pneumonia discharge  Withholding of all inpatient Medicare payments  Up to 2% in 2014  Up to 3% by 2015 and beyond2  Total 2013 impact3  $280M withheld  2,217 hospitals impacted 1 Dharmarajan K, Hsieh AF, Lin Z, et al. Diagnoses and Timing of 30-Day Readmissions After Hospitalization for Heart Failure, Acute Myocardial Infarction, or Pneumonia. JAMA. 2013;309(4):355-363. Linden A, Adler-Milstein J. Medicare disease management in policy context. Health Care Finance Rev. 2008;29(3):1-11. 2 CMS Hospitals Readmissions Reductions Program of the Patient Protection and Affordable Care Act (PPACA), 2010. 3 - http://www.kaiserhealthnews.org/stories/2012/october/03/medicare-revises-hospitals-readmissions- penalties.aspx?referrer=search 2014 CMS Benchmark Target 30-day Readmissions Rate1

6868 CardioMEMS™ HF System and Pressure Monitoring Weight and BP Impedance Pressure No Reduction in HF Hospitalizations Poor Marker (TIM-HF, TELE-HF) No Reduction in HF Hospitalizations High false positives (DOT-HF) Significant Reduction in HF Hospitalizations Right marker, Right management approach (COMPASS, CHAMPION, HOMEOSTASIS™) CardioMEMS PA Pressure The Right Approach to Management of HF

6969 COMPASS HOMEOSTASIS™ CHAMPION  Right Parameter – Pressure  Right Patients – Class III  Right Approach – Management to target pressures and physician directed patient self management  Right Parameter – Pressure  Right Patients – Class III  Right Approach – Management to target pressures  Right Parameter – Pressure  Right Patients – Class III showed significant benefit Wrong Patients – Including Class IV resulted in no benefit Wrong Approach – Management to pressure spikes X X Multiple Studies have Shown that Pressure Monitoring is the Right Strategy to Reduce HF Hospitalization

7070 CumulativeNumberofHFRHospitalizations 0 20 40 60 80 100 120 140 160 180 200 220 240 260 Days from Implant 0 90 180 270 360 450 540 630 720 810 900 270 262 244 210 169 131 108 82 29 5 1 280 267 252 215 179 137 105 67 25 10 0 No. at Risk Treatment Control Primary Endpoint Treatment Control CHAMPION Trial: Primary Endpoint Met Cumulative HF Hospitalizations Reduced At 6 Months and Full Duration Abraham WT, Adamson PB, Bourge, RC et al. Wireless pulmonary artery hemodynamic monitoring in chronic heart failure: a randomized controlled trial. The Lancet. 2011:377;658-66. 28% Reduction at 6 months 37% Reduction at Full Duration

7171 CHAMPION Trial: Principal Findings Pulmonary Artery Pressure Monitoring Medication Changes Based on PA Pressure p<0.0001 <1 medication change per patient per month Pulmonary Artery Pressure Reduction p=0.0077 Heart Failure Hospitalization Reduction p=0.0002 Quality of Life Improvement p=0.0236 *p values for Treatment vs Control Group Abraham WT, Adamson PB, Bourge, RC et al. Wireless pulmonary artery hemodynamic monitoring in chronic heart failure: a randomized controlled trial. The Lancet. 2011:377;658-66.

7272  Nearly half of all HF admissions are for patients with preserved Ejection Fraction1  Limited treatment options available  Currently not candidates for ICD or CRT therapy CMS ADHF Admissions1 HF-pEF HF-rEF not assessed 43.6% 38.8% 17.6% 1 Kociol et al AHJ 2010 HF Patients with Preserved EF – An Even Bigger Challenge to Manage

73 HF Management with CardioMEMS™ HF System Reduced HF Hospitalization in Preserved EF Patients 0% 10% 20% 30% 40% 50% HFrEF HFpEF P<0.0001 vs control P=0.0085 vs control RelativeRiskReduction HF Hospitalization Reduction (6 mos follow-up) reduced EF (<40%) preserved EF (>40%) 1Kociol et al AHJ 2010 2 Adamson PB et al. CardioMEMS Heart Sensor Allows Monitoring of Pressures to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) Trial: Impact of Hemodynamic Guided Care on Patients with Preserved Ejection Fraction. Additional updated data on file.  In the US, nearly half of HF admissions are for patients with preserved EF1  HF management guided by the CardioMEMS HF System reduced HF hospitalizations in patients with either preserved or reduced EF2  The CHAMPION trial is one of the first successful management strategies to reduce HF hospitalization in this patient population

7474 Intervention Trial Mean Duration of Randomized Follow-Up Annualized Reduction in HF Hospitalization Rates Number Needed to Treat (NNT) per year to Prevent 1 HF Hospitalization Beta-blocker COPERNICUS 10 months 33% 7 Aldosterone antagonist RALES 24 months 36% 7 Cardiac resynchronization CARE-HF 29 months 52% 7 Beta-blocker MERIT-HF 12 months 29% 15 ACE inhibitor SOLVD 41 months 30% 15 Aldosterone antagonist EMPHASIS-HF 21 months 38% 16 Digoxin DIG 37 months 24% 17 Angiotensin receptor blocker Val-HeFT 23 months 23% 18 Angiotensin receptor blocker CHARM 40 months 27% 19 Pulmonary artery pressure monitoring at home CHAMPION 17 months 33% 4 Clinical Significance of CHAMPION Results

75 CardioMEMS™ HF System Reimbursement  Hospital Inpatient  Established ICD-9 procedure code for implant (38.26)  Maps to DRG 264 – average base payment with adjustments of $17,820  CardioMEMS™ HF System has applied for New Technology DRG Add-On Payment  1 of 7 applications CMS will review  If approved, effective October 1, 2014 for 2-3 years  If approved, provides up to 50% of cost of device + DRG payment  Physician  Implant  Physician may bill for right heart catheterization + pulmonary angiography (established codes) + sensor implant (unlisted CPT code)  For unlisted codes physician uses a comparable procedure  Remote Monitoring  Current coding applies (same as CRM) – Monthly

76 CardioMEMS™ HF System Launch Readiness  The manufacturing capacity and the inventory needed to launch the CardioMEMS HF system product line in the U.S. are already in place  We do not need to add sales representatives to support this launch  Market development will take time, but we are ready to begin launching the CardioMEMS HF system product line in the U.S. after the product is approved by the FDA

77 CardioMEMS™ HF System Summary  CardioMEMS HF system is the right product for the right market at the right time  We think the CardioMEMS HF system product line can become a significant new growth driver for St. Jude Medical

7878 Panel for Question and Answer Session

Power of the EP Portfolio Eric S. Fain, M.D. – Group President

8080 2014 Estimated Worldwide EP Market Size Revenue in Millions EP Ablation Catheters $1,000 35%EP Diagnostic Catheters $680 23% Mapping/ Navigation/ Recording $550 19% Access $370 13% ICE/Other $300 10% 2014 Market Revenue $2.9B Market Growth: 9% - 11%

81 Treated with Catheter Ablation 2.2% 2014 ~$58 Billion ~12.9M Symptomatic AF ~$1.3B market Treated with Catheter Ablation 1.9% 2013 ~$56 Billion ~12.5M Symptomatic AF Estimated WW AF Market Opportunity AF is the fastest growing market segment within the EP space Treated Population ~3% CAGR (Sources: MRG, HRI, Miyasaka – Circ 2006, WHO 2002, US Census Bureau, STJ estimates) ~$4,500/case 19% Growth Diagnosed Symptomatic AF Population ~$1.1B market AF Diagnosed Symptomatic AF Population AF Population treated w/ Catheter Ablation

8282 Growth in AF Ablation Procedures - 50,000 100,000 150,000 200,000 250,000 300,000 350,000 2011 2012 2013 est. 2014 210,000 250,000 295,000 350,000 ’11 - ’14 CAGR = 19% WW AF Ablation Procedures Catheter and Surgical

8383 Favorable STJ Dynamics In A Growing Market  High interest in differentiated STJ technology  MediGuide™ Technology  TactiCath™ Quartz Contact Force Ablation Catheter (Endosense)  Advanced portfolio of ablation solutions  Building foundational clinical data  CABANA  EAST  STAR VT  Toccata/Efficas/Toccastar  Unmet need for optimized workflow and procedural efficiencies

84 MediGuide™ Technology – Cornerstone of the Integrated Lab  Expand STJ presence through our Integrated Lab offering  Reducing radiation  Increasing workflow efficiency and reducing healthcare costs  Potential for improving patient outcomes  MediGuide Technology  3D visualization and precise navigation platform across EP and CRT procedures  Enables navigation of devices on pre-recorded fluoroscopy and enhances performance of EnSite™ Contact Force Module

85 The MediGuide™ Technology Platform Continues to Grow  Increasing adoption as we continue to build synergies with STJ’s broad portfolio of catheters and tools  Additional CRT tool options 2H 2014  Strong clinical evidence demonstrating radiation reduction for increased patient and laboratory staff safety  Numerous Single Center and Multi-Center studies published in 2013  Potential for increased procedural/economic efficiencies and improved patient outcomes

8686 2014 Advanced Ablation Solutions St. Jude Medical Advanced Ablation Solutions TactiCath™ FlexAbility™ Catheter EnSite™ Precision™ Ampere™ WorkMate Claris™ Agilis™

87  Extensive thought leader involvement throughout design and testing to result in best in class workhorse catheter  Flex irrigated electrode tip  Full portfolio of curve shapes, including asymmetric options FlexAbility™ Ablation Catheter  Handle and shaft that performs across the range of EP procedures, including transeptal and retrograde approaches  Platform for future MediGuide™ sensors  CE Mark and FDA approval anticipated 2H 2014

TactiCath™ Quartz Ablation Catheter  Irrigated ablation catheters featuring contact force technology  Technology acquired in 2013 from the Endosense acquisition  Commercially available today in Europe and other International markets  FDA approval with AF indication anticipated 2H 2014

8989 Ampere™ RF Ablation Generator  Complete redesign of hardware and software to improve workflow and optimize the integrated lab experience with:  Intuitive design and adjustable settings  High fidelity signals  New features, including power control mode and remote control  CE Mark approved end 2013 and FDA approval anticipated 2H 2014

WorkMate Claris™ Recording System  Only fully integrated EP system on the market with stimulation  Redesigned hardware and software for exceptional signal clarity  Easier, more efficient analysis of patient data, including Application Control software for protection and compliance  Enhanced productivity through system integration and data workflow integration for one, electronic patient record  First commercial availability in Europe and the US end 2013

9191 EP Summary  AF is an expensive, epidemic disease  The potential market for innovative medical devices that help reduce the cost of care and improve outcomes for patients who suffer from AF is only 2% penetrated  We expect revenue from our AF business to continue to grow at a high single digit or low double digit rate in 2014 driven by our product innovation

A special focus on Endosense Srijoy Mahapatra, M.D., FHRS - VP, Clinical, Medical & Scientific Affairs

9494 2014 Estimated Worldwide EP Market Size Revenue in Millions *Estimated current market share 2014 Market Revenue $2.9B Market Growth: 9% - 11% EP Ablation Catheters $1,000 35% EP Diagnostic Catheters $680 23% Mapping/ Navigation/ Recording $550 19% Access $370 13% ICE/Other $300 10% STJ 14%*

95 Solution II: Flex Tip with best in class maneuverability Solution I: Leading the way with Contact Force 2014: A New Era for STJ Ablation Catheters TactiCath™ Quartz Ablation Catheter Commercial in International Markets FDA Approval Anticipated 2H 2014 FlexAbility™ Ablation Catheter CE Mark Anticipated 2H 2014 FDA approval Anticipated 2H 2014

9696 TactiCath™ Quartz Contact Force Ablation Catheter Background (Force Sensing)  Pioneering solution to give physicians a real-time, objective measure of the force they apply to the heart wall during a catheter ablation procedure  CE Mark approved for AF and supra ventricular tachycardia (SVT) ablation  U.S. IDE clinical trial complete; anticipating FDA approval with an AF indication in 2H 2014

97 Why Contact Force? Safely create durable transmural lesions Time. Power. Force.

98 Established Clinical Value for TactiCath™ Contact Force Ablation Catheters TOCCATA • Safety and feasibility of Force Sensing EFFICAS I • Contact Force parameters on minimum values and Force Time Integral EFFICAS II • Significantly better outcome using Contact Force TOCCASTAR • IDE clinical data

99  Optimal Force leads to reduced recurrence of AF TactiCath™ Ablation Catheter Guidelines for Force Sensing 1. Reddy et al.; The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm, 2012 Nov;9(11):1789-95. 2. Neuzil et al. Electrical reconnection after pulmonary vein isolation is contingent on contact force during initial treatment: results from the EFFICAS I study. Circ Arrhythm Electrophysiology. 2013 Apr;6(2):327-33.

100 TactiCath™ Ablation Catheter Clinical Findings Reddy et al.; The relationship between contact force and clinical outcome during radiofrequency catheter ablation of atrial fibrillation in the TOCCATA study. Heart Rhythm, 2012 Nov;9(11):1789-95. 0 20 40 60 80 100 0-10 g 10-20 g 20+ g 100% 53% 80% 47% 20% No successSuccess 100% 80% 60% 40% 20% 0% Using Force less than 10g leads to AF recurrence; Greater than 20g for each lesion is good target

101 TOCCASTAR Study Study Design  Prospective, multicenter (EU & US), IDE study  Randomized TactiCath™ Ablation Catheter vs. Biosense Webster ThermoCool™; non-inferiority comparison  Safety and effectiveness study, 12 months follow-up post PVI  317 patients with paroxysmal AF  Expect results to be presented at HRS; intend to publish findings in a leading medical journal  Trial completed, PMA submitted  Anticipate FDA approval 2H 2014 (AF indication)

102102 TactiCath™ Quartz Ablation Catheter Advantages TactiCath ablation catheter's proprietary optical sensor technology leads to potential clinical advantages over other sensing alternatives Technical Feature Potential Clinical Advantage Fiber optic sensing Force measured closer to tip Force measured where power applied 50Hz sampling rate (vs. 20Hz) Higher rates allow visualization of transient peaks with cardiac movement and increase the feeling of real-time feedback No calibration required Saves time and shortens procedure Other sensor needs recalibration as often as every 15 min due to temperature changes

103103 Integration Update  Functional transitions completed in Q4 2013  Development, manufacturing, and quality functions have been integrated into St. Jude Medical  European sales teams are fully commercial  FDA PMA Submission Complete  Submitted Continued Access Protocol  Expect CAP cases 1H 2014  Anticipated FDA approval 2H 2014 (AF indication)

104 Part II: New Era for STJ Ablation Catheters Solution: Flex Tip with best in class maneuverability and signal quality FlexAbility™ Ablation Catheter CE Mark and FDA approval anticipated 2H 2014  Internal STJ Development Project  Elite KOLs supporting efforts with pre-clinical evaluations to ensure steady stream of feedback throughout the process  Share gaining opportunity with workhorse device that is complementary with TactiCath™ ablation catheter with premium contact force technology

105  Flex Tip is a critical element incorporated into design  International Markets have the first generation Flex Tip available; it is the best selling STJ ablation catheter in both Europe and Japan  To achieve best in class maneuverability, we launched a collaborative effort between clinical, R&D, and external physicians  Features targeted for optimized performance include: durability, signal quality, handling, and lesion quality  22 EP’s have validated multiple design iterations over the past 6-months via pre-clinical effort FlexAbility™ Ablation Catheter

106106 Ablation Catheter Summary  One of the most significant new growth drivers in our AF business for 2014 will be the launch of our TactiCath contact force sensing line of ablation catheters  Physician feedback leads us to believe that contact force sensing catheters may help improve the safety and efficacy of AF ablation procedures  During 2014, we expect to launch both TactiCath™ and FlexAbility™ lines of ablation catheters and gain share in the $1 billion ablation catheter segment of the EP market

Executing on a robust CV portfolio Eric S. Fain, M.D. – Group President

109109 STJ PCI Optimization™ Leadership in 2013  We are the WW leader in the fast-growing market of FFR-guided interventions for coronary artery disease  The global market for FFR products exceeded $250 million in 2013 with strong double digit growth  We believe we will take share and continue to grow the FFR market in 2014  We are driving OCT market expansion  We grew our OCT disposables revenue double digit as customers switched from IVUS to OCT  We are advancing the field of imaging with even higher resolution, new stent planning tools and 3D reconstruction  We are the leader in clinical evidence development for FFR and OCT  FAME I, FAME II, FAME III, ILUMIEN I

110 FFR & OCT Markets Underpenetrated & Growing 0% 5% 10% 15% 20% 25% 30% 35% 40% FFR OCT IVUS  Revenue growth driven by STJ technologies: FFR & OCT  Growth in OCT at the expense of IVUS  Even at today’s low penetration rates, the current combined market for IVUS, FFR and OCT is ~$800 million 2012 2013 2014* FFR, OCT & IVUS Penetration - WW * 2014 penetration rates are projected 2012 2013 2014* 2012 2013 2014*

111111 2014 PCI Optimization™ System Growth: Driven by Workflow Enhancement, Technology Advancement, and Clinical Outcomes Workflow • Pre-installed, ready to use FFR into all new cath lab systems • Fully integrated OPTIS™ systems • Leverage growing install base of ILUMIEN™ OPTIS™ system and QUANTIEN™ platform Technology • Launch new PressureWire Aeris™ system • Roll out automated stent planning tools & 3D reconstruction • Introduce angio co-Registration with OCT Outcomes • Adoption of appropriate use criteria • Leverage FAME clinical programs • Now funding FAME III • Build upon ILUMIEN™ OCT clinical program

112112 Nearly all hemodynamic/cath lab systems sold today have Aeris-compatible FFR pre- installed, making every recipient a potential customer with no capital purchasing barrier Pre-installed FFR into Nearly All New Cath Lab Systems Workflow Enhancement Drives Penetration

113113  STJ’s first cath lab-integrated PCI optimization™ platform, offering both anatomical (OCT) and physiologic (FFR) assessment  Always there, always on, no barriers for usage  Provides competitive advantage  Limited launch anticipated 2H 2014 Workflow Enhancement Drives Penetration Fully Integrated OPTIS PCI Optimization™ System

114114 Technology Advancement Drives Preference  The only wireless FFR system on the market  Designed for quick access and smooth stent delivery  Near 1:1 torque response matching frontline workhorse guidewires  Incorporates new miniaturized radio transmitter for better maneuverability and margin improvement  Launch ongoing 9th Generation PressureWire Aeris™ System PressureWire Aeris 9th generation PressureWire

115115  Directly links OCT with angiography-- the standard of care imaging modality  Provides for more accurate lesion assessment and stent deployment compared to angio or OCT alone  Accelerates the OCT learning curve  Limited launch anticipated 2H 2014 Technology Advancement Drives Preference Angio Co-Registration with OCT

116116 Clinical Outcome Drives Penetration FAME Clinical Program Influenced Appropriate Use Criteria FAME Clinical Program AUC & Expert Consensus supports the use of FFR

117 Left Atrial Appendage Closure  We expect LAA closure to become an essential tool in the tool box of full-service EP and interventional practices  STJ has wide access to AF patients through existing sales channels  Full commercialization of the AMPLATZER™ Cardiac Plug (ACP) is underway in approved markets  Stable market share in a market with strong double digit growth  LAA closure device inclusion in ESC guidelines has helped contribute to market growth

118 LAA Closure – Amplatzer™ Amulet device  2nd generation device  Improves upon an already successful ACP device  Pre-loaded in catheter sheath to improve ease-of-use  Addresses a broader range of patient anatomies  Expect European launch in 2H 2014 AMPLATZER™ Amulet Disc and Proximal End Screw

119 LAA Closure – Re-launch U.S. IDE Study  The ACP IDE trial enrollment was stopped in December 2013  Trial was an event-driven design comparing LAA to OAC and requiring up to 3000 patients  Made decision to stop enrollment due to expected near-term approval of a competitive device and potential enrollment challenges  No safety or efficacy issues  Currently working with FDA on a revised trial design which should result in an accelerated time to market  Expect to start enrollment in 2H 2014

120 Renal Denervation Update  We remain optimistic about renal denervation as a potential new growth driver  Hypertension is an expensive, epidemic disease that has significant clinical and cost implications for physicians, hospitals, payers and patients  Like many early stage therapies, we recognize there is a lot to learn – at this time there are more questions than answers  What we do know is that renal denervation has consistently been shown to be safe  We also know that STJ has a strong history with RF ablation technologies  The internally developed EnligHTN™ system uses a multi- electrode system that differs from the competitive system  We look forward to reviewing the SYMPLICITY HTN-3 clinical trial results with our Global Renal Denervation Advisory Board and the EnligHTNment Clinical Trial Steering Committee and will incorporate lessons learned into our program

121 Tissue Valves Represent a Growing Segment for STJ 2009 2010 2011 2012 2013 2014E  TAVR has helped the surgical aortic valve replacement (SAVR) market to grow through increased patient referrals  Since the launch of the Trifecta™ valve, STJ has almost doubled tissue valve revenue through market growth and share gains STJ Tissue Heart Valve Market Share STJ Tissue Heart Valve Revenue $0 $50 $100 $150 $200 $250 $300 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014E Millions Trifecta Milestones: CE Mark 2010 FDA 2011 PMDA 2012

122122 CV Summary  PCI optimization™ is a large potential opportunity where we lead in innovation, clinical development and market expansion  We expect a steady improvement in our growth rate as we continue to transition our sales mix from legacy products to growth drivers  We are optimistic that in 2014 our tissue heart valves, FFR, OCT and LAA will continue to grow at a high single digit or low double digit rate

A deeper dive into Portico™ Transcatheter Aortic Valve Phil Ebeling – Sr. Vice President, R&D Device referenced is approved for CE Mark. Not available for sale in the U.S.

125 Market Opportunity Diagnosed Prevalence (Severe Aortic Stenosis): 500K 25% TAVR penetration Patients (US/EMEAC/Japan) 125K Estimated 2013 Market Size ~$1.0B Forward 5 Year CAGR 17% Market Opportunity $2.5-3.0B Transcatheter Aortic Valve Replacement (TAVR)

126 Positive Market Dynamics for TAVR Positive Dynamics  650 WW TAVR centers today  Favorable reimbursement in place in 8 OUS geographies  Long term clinical and economic evidence is available and supports TAVR  Improving overall TAVR outcomes (improved patient selection, lower profile devices)  TAVR moving into lower-risk patients (SURTAVI, PARTNER II) $329.1 $470.6 $648.5 $738.3 $0 $200 $400 $600 $800 $1,000 $1,200 $1,400 2013 2014 RevenueinThousands ID U.S. $978 $1,209

127127 Portico™ Transcatheter Aortic Valve offers a design alternative to many existing TAVR limitations and challenges  Designed to be fully resheathable and repositionable  Designed to mitigate heart block  Designed to minimize PV Leak  Designed to minimize coronary ostia blockage post implantation  Designed for maximum durability

128128 Portico™ Transcatheter Aortic Valve is designed to be fully resheathable and repositionable*  The unique valve and delivery system design of Portico heart valve allows the ability to fully reposition the valve:  Resheath the valve proximally or distally*, in situ  Retrieve the valve, if necessary  Resheathability is designed to enable optimized valve positioning during implantation and helps insure better outcomes (ex: PV Leak) *Until fully deployed Manoharan, G., St. Jude Medical Portico™ Transcatheter Aortic Valve Clinical Experience, EuroPCR, 05/17/2012.

129 Portico™ Transcatheter Aortic Valve is designed to mitigate heart block  Designed to address conduction system interference  Ability to fully reposition the valve in situ for improved placement accuracy  Valve placed low within the stent frame allows for sealing without the valve extending deep into the LVOT  Nonflared annulus section of the stent frame Valve placed low within the stent frame Nonflared annulus section of the stent

130 Portico™ Transcatheter Aortic Valve is designed to minimize PV Leak Calcific nodules  Single porcine pericardium cuff seam  The large cells in the annulus section of the stent are designed to minimize the risk of PV leak  Less metal — minimizing the potential of a stent strut resting against a calcific nodule  More tissue — allowing the tissue to conform around calcific nodules Paravalvular Leak Simulation

131 Portico™ Transcatheter Aortic Valve is designed to minimize coronary ostia obstruction post implant  Large stent cells in the aortic section of the stent, allows access to coronary ostia post-implant Manoharan, G., St. Jude Medical Portico™ Transcatheter Aortic Valve Clinical Experience, EuroPCR, 05/17/2012. Aortic Section Annulus Section

132  Portico transcatheter aortic valve is designed for leaflet coaptation in round and elliptical annulus configurations  In vitro testing is completed over the valve’s use range and in various annulus configurations to assess durability and hemodynamic performance Circular Configuration Ellipse 0° Ellipse 90° Portico™ Transcatheter Aortic Valve is designed for maximum durability and hemodynamic performance

133 * Manoharan, G., How New Designs Lead to Improved Clinical Results in TAVR, TCT 2013

134 Portico™ Transcatheter Aortic Valve US IDE Pivotal Trial, CE Mark Update  Full IDE approval using 23 & 25mm valves at 40 US sites in a head to head trial with other TAVR valves  ~1610 patients split into high and extreme risk cohorts  Randomized against commercially available TAVR valves  Primary non-inferiority endpoint for all-cause mortality and disabling stroke at one year  27 & 29mm will be added in the trial in 2H 2014  FDA has indicated that TAVR is now considered established rather than novel  FDA has recently engaged STJ on alternative trial designs that should significantly reduce the size and duration of the trial  STJ will start enrollment under current design and use patients toward future analysis  On track for the first implants in 1H 2014  CE Mark  23, 25mm valves - market released  27, 29mm valves - enrollment to begin 1H 2014, commercialize 2H 2014

135135 Next Generation Portico™ Transcatheter Aortic Valve – Product Pipeline  Delivery System Designs:  Improved placement accuracy (co-axial alignment of the valve)  Reduction in vascular complications (further profile reduction)  Improved user interface (ergonomics)  Valve Designs:  Further minimization of PV Leaks (integrated solutions)  Broader range of valve sizes

136136 Portico™ Transcatheter Aortic Valve Summary  Positive clinical and economic evidence is driving the growth of the TAVR market  Portico transcatheter aortic valve is a next generation product line that addresses many existing TAVR limitations and challenges and is expected to become a competitive new growth driver for St. Jude Medical

Growth through innovation in Neuromodulation Eric S. Fain, M.D. – Group President

139 Plano Warning Letter Resolution  Completed all remediation activities associated with the Plano site Form 483’s and warning letter  Anticipate FDA re-inspection by end of 1H 2014

140 WW Neuromodulation Dynamics  Approximately $2.0 billion market in 2014  ~$1.5B chronic pain; ~$0.5B deep brain stimulation  Expect both the US and International markets will grow at a mid to high single digit rate in 2014  Payers increased focus on clinical outcomes  Market fundamentals support continued strong growth  Severely under penetrated market  Increasing stigma and impact from long-term opioid use  Growing evidence for improved outcomes and healthcare economics with earlier intervention  Opportunities for share capture through innovation  Leverage innovation resident in CRM devices and bring to SCS/DBS systems  Create novel stimulation modes and explore anatomical targets  Expand indications

141 SCS for Chronic Pain: Need for alternative stimulation modes  SCS for Neuropathic pain is an accepted standard of care in the treatment of chronic pain  However, as therapy adoption grows there is increasing awareness of SCS non- responders or patients who become non- responders over time  Anecdotal evidence suggests as high as 20- 30% of CP market (over time)  Little predictive evidence to say who will respond/not respond  Increasing market need for an alternative stimulation mode to address non- responders

142 Evolution of Stimulation Modes to Tune Therapy Tonic  Standard waveform in today’s devices  Relatively low energy  Recharge ~1-2 hours, ~2 times per week High Frequency  Reduces paresthesia  Rapid battery drain  Recharge ~4-6 hours, 1-2 times daily STJ Burst  Reduces paresthesia  Minimal battery drain  Recharge ~1-2 hours, ~2 times per week

143 Lateral Discriminatory Pathway Medial Affective/Attentional Pathway Pain Perception Attention to pain Why Burst Stimulation? Pain processing patterns and pathways  Lateral discriminatory pathway – controls pain perception  Medial affective/attentional pathway – controls emotional response and attention to pain stimuli IPG stimulation patterns and pathways  Tonic – Modulates only the lateral pathway  Burst – Modulates both the lateral and medial pathways to maximize effectiveness 1. Jahnsen H, Llinás R. : Voltage-dependent burst-to-tonic switching of thalamic 2. Harvey A. Swadlow1 & Alexander G. Gusev : The impact of 'bursting' thalamic impulses at a neocortical synapse. Nature Neuroscience 4, 402 - 408 (2001). 3. Sherman SM : A wake-up call from the thalamus. Nature neuroscience, 2001 cell activity: an in vitro study. Arch Ital Biol. 1984 Mar;122(1):73-82. 4. DeRidder D, Plazier M, Kamerling N, Menovsky T

Add a comment

Related presentations

Gage-Cannon Investor Services

Gage-Cannon Investor Services

November 10, 2014

Gage-Cannon helps ventures accelerate organic growth or obtain equity funding, and...

Mavenir Analyst Day

Foro MAB Sevilla 13 de noviembre de 2014

ING Q3 2014 Earnings Report

ING Q3 2014 Earnings Report

November 5, 2014

Analyst presentation third quarter 2014 results. ING posts 3Q14 underlying net pro...

Related pages

Media Advisory: TransAlta 2014 Investor Day Conference ...

CALGARY, ALBERTA--(Marketwired - Oct 29, 2014) - TransAlta Corporation (TA.TO)(TAC) will host its 2014 Investor Day on Friday, November 14 in ...
Read more

Safeguard Scientifics' CEO Hosts 2014 Investor Day ...

Safeguard Scientifics, Inc. (NYSE:SFE) 2014 Investor Day Conference Transcript October 15, 2014 8:00 AM ET Executives John Shave - Senior Vice President ...
Read more

Cisco to Host Investor Day Conference 2014 Webcast - Yahoo ...

SAN JOSE, CA--(Marketwired - May 12, 2014) - Cisco (NASDAQ: CSCO) will host its Investor Day Conference webcast on Tuesday, May 20, 2014 from ...
Read more

Ford Hosts 2014 Investor Day Conference

DEARBORN, Mich, Sept. 16, 2014 - Ford Motor Company (NYSE:F) will host an Investor Day conference that begins at approximately 1 p.m. EDT Monday, Sept. 29 ...
Read more

Investor Day 2014 - Home - Bombardier Inc. Investor Relations

Investor meetings. Webcast(s) Streaming. Webcast. Download. Related documents. ... Bombardier Transportation RCS - Investor Day 2014 (PDF, 951.1 kB) Add.
Read more

Ford to Host 2014 Investor Day Conference | Business Wire

Ford Motor Company (NYSE:F) will host an Investor Day conference that begins at approximately 1 p.m. EDT Monday, Sept. 29, 2014. The event will featur
Read more

Value Investor Conference

Annual Value Investor Conference at the University of Nebraska, College of Business Administration prior to the Berkshire Hathaway annual meeting. An ...
Read more

Tesoro's CEO Hosts 2014 Analyst and Investor Day ...

Tesoro Corporation (NYSE:TSO)2014 Analyst and Investor Day Conference December 10, 2013 9:00 am ET Executives Brian Randecker Gregory J. Goff - Chief Executive
Read more

Cisco to Host Investor Day Conference 2014 Webcast | The ...

SAN JOSE Calif., May 12, 2014 - Cisco will host its Investor Day Conference webcast on Tuesday, May 20, 2014 from San Francisco. The event is part of Cisco ...
Read more

Investools Investor Education Conference 2014 Official ...

Your inspiration destination. The 2014 Investools Investor Education Conference is a three-day investing education event taking place on August 18-20, 2014 ...
Read more